NCT05166304

Rebamipide in Patients With Active Rheumatoid Arthritis

Rebamipide as an Adjunct to Methotrexate in Patients With Active Rheumatoid Arthritis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: October 6 University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Although the aetiology of RA remains to be fully elucidated, interleukin (IL)-17 are believed to play a critical role in the pathogenesis of RA. Rebamipide is an antiulcer drug that protects gastric epithelial cells,improves gastric defense mechanisms by increasing gastric mucus. Rebamipide inhibited interleukin (IL)-17, also it inhibits IL-1β-induced RASF proliferation.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	Rebamipide	patients will receive the standard therapy plus 100 mg Rebamipide three times daily
DRUG	Placebo	patients will receive the standard therapy (methotrexate) plus placebo tablets

Timeline

• Start date: 2024-01-01
• Primary completion: 2025-08-01
• Completion: 2025-09-01
• First posted: 2021-12-21
• Last updated: 2025-11-20

Locations

1 site across 1 country: Egypt